Back to search results

Healthy Volunteers Study for Ovarian Cancer Early Detection

This study is looking at how the bacteria in your body (microbiome) and their byproducts (metabolites) might help us find ovarian cancer earlier. Researchers will collect vaginal swabs and stool samples from healthy women aged 30 to 50 who have ovaries and no history of cancer or genetic risk factors for ovarian cancer. These samples will be compared to those from women with a higher risk or an ovarian cancer diagnosis. The goal is to see if these samples can help predict or detect ovarian cancer development. The study is currently unclear on its recruitment status and plans to enroll 50 participants.

Study design
This is an observational study planning to enroll 50 healthy women. It is not a treatment study.
What's involved
You would provide a vaginal swab at a clinic appointment and a stool sample within one week of the swab.
Compensation
Not stated in the trial record.
Follow-up
The study involves a one-time sample donation; there is no specified follow-up period after sample collection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06962059

Healthy Volunteers Study

Recruiting
Not specifiedAges 30–50Observational
Abramson Cancer Center at Penn Medicine
~50 participants
Updated 2026-02-05 on ClinicalTrials.gov
What's tested:Self-Administered Sample Collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Microbiome Involvement
Measured over One-time sample donation of vaginal swabs collected at the time of the patient's appointment. A subsequent stool sample will be provided within a week of the vaginal swab.
+1 more outcome measured

Conditions

Ovarian Cancer
Genetic Predisposition to Disease

Explore related trials

Malignant Ovarian Neoplasm

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Susan Domchek, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

Catherine Wolfe, BA
[email protected]
215-360-0422
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

has ovaries

Exclusion

genetic mutations which increase risk of ovarian cancer: BRCA1/2, BRIP1, PALB2, Lynch Syndrome (MLH1, MSH2/EPCAM, MSH6) and ATM
no genetic testing results or unknown genetic status
prior cancer diagnosis
prior cancer treatment
HRT use
Antibiotic use (1 month prior to providing sample)

What this trial measures

  • Microbiome InvolvementOne-time sample donation of vaginal swabs collected at the time of the patient's appointment. A subsequent stool sample will be provided within a week of the vaginal swab.

    Investigate the involvement of the microbiome and associated metabolites in ovarian cancer.

  • Predictive ModelOne-time sample donation of vaginal swabs collected at the time of the patient's appointment. A subsequent stool sample will be provided within a week of the vaginal swab.

    Generate a predictive model for ovarian cancer risk and progression. Healthy volunteers will provide a control group to compare to BRCA-carrier and affected cohorts consented through the CREP Biobank study in order to mechanistically understand the function of the identified metabolites in disease prevention, initiation, progression, and treatment response.